The PennZone

  • Home
  • Non-profit
  • Education
  • Business
  • Construction
  • Health
  • Technology
  • Entertainment
  • Software

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • EDC Weekend Comedy Special Featuring Don Barnhart & Friends — Use Promo Code FRIEND for 50% Off
  • N Y S E: OTH Off The Hook YS Is Building a Vertically Integrated Marine Empire — And Investors Are Starting to Notice
  • Concierge Title Agency Merges with Independence Title, Inc. to Deliver an Expanded Concierge Closing Experience Across South Florida
  • Together We Dance Foundation Steps Up for Family in Need of Safe Transportation
  • Grow My Security Company Launches Next-Generation Website and Expands Strategic Marketing Solutions for the Security Industry

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • $4.8M in Contracted AI Revenue with Projections of $30M Over 6-12 Months for Diversified AI Software and Platform-Based Services Provider XMax Inc
  • Michelangelo's Great Secret Hiding in Plain Sight
  • Virginia Marchese's Paradox: A Nation Still Deciding Who Belongs Examines Race, Migration, Law, and America's Unfinished Struggle for Equality
  • From Blank Page to Published Book
  • Larry R. Wasion's Jump Gate III RoadMaker Blends Cutting-Edge Sci-Fi with High-Stakes Space Exploration and Complex Technologies

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business, Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • SmartCone and Samsung Launch RoadDefender™ to Enhance Real-Time Safety for Roadside Workers
  • The Personal Development Industry Has a Blind Spot Says Global Personal Success Guru Omar L. Harris
  • Kevin "Mr. Wonderful" O'Leary Begins New Universal Coin & Bullion Promotion of Gold and Silver
  • Flamingo Compliance Launches Schengen Area Trip Planning Tools as New Digital Border Controls Take Effect
  • HHS Announces Major Push to Address Psychiatric Drug Risks: CCHR Applauds Focus on Informed Consent and Safe Tapering
  • PhaseZero Launches Eight AI Agents for Manufacturers and Distributors - Connecting Sales, Support, and Operations Teams Across Full Commerce Journey
  • @tickerbitcoinbb and @girl_still_cute Announce the Arrival of SPROTO AEON BABY 1.0 – A New Chapter for the HarryPotterObamaSonic10Inu Universe
  • Michigan Fitness Foundation Gifts EPEC Moves K–5 PE Curriculum Program to Educators during Michigan Moves Month
  • Sidow Sobrino, the One and Only World's No.1 Superstar®, Launches Dangerous Joy
  • Modern Site Builders Launches WolfResume.com, an AI Career Kit Built for ATS Hiring
  • Slotozilla Expands Bonus Portfolio and Affiliate Reach Following iGB Barcelona 2026
  • ThoroughCare Expands Remote Patient Monitoring with Withings Integration
  • Wellsboro Earns Gold Bird Town Certification, Highlighting Conservation Leadership
  • XMax Inc. (N A S D A Q) Accelerates AI Expansion With $4.8 Million Contracted Revenue, $30+ Million Enterprise Pipeline and Strategic SpaceX Exposure
  • Lnk.Bio Becomes the First Link-in-Bio Service Fully Manageable from Inside ChatGPT
  • Did Drake Just Find His Next Signee? Peoria Rapper Rhymi Gifts "ICEMANDRAKE" Domains, Drops Debut Album Same Day
  • Andrew Tate Says Los Angeles Is "Where I Belong" as He Hints at USA Move
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • VeneerVibe Releases 2026 Snap-On Veneers Market Report

Popular on PennZone

  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph - 131
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
  • A Powerful Beginning Inside One of Philadelphia's Most Inspiring Early Childhood Education Centers
  • AWARENESS TO WELLNESS: Imhotep Institute Charter High School
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • Best Companies Group Launches Free Top Companies to Work for in Arizona Program

Similar on PennZone

  • T. Jones Group Named Finalist Across Multiple Categories at the 2026 Georgie Awards
  • The Simplest Small Business You're Probably Not Thinking About
  • EDC Weekend Comedy Special Featuring Don Barnhart & Friends — Use Promo Code FRIEND for 50% Off
  • N Y S E: OTH Off The Hook YS Is Building a Vertically Integrated Marine Empire — And Investors Are Starting to Notice
  • Concierge Title Agency Merges with Independence Title, Inc. to Deliver an Expanded Concierge Closing Experience Across South Florida
  • Grow My Security Company Launches Next-Generation Website and Expands Strategic Marketing Solutions for the Security Industry
  • $4.8M in Contracted AI Revenue with Projections of $30M Over 6-12 Months for Diversified AI Software and Platform-Based Services Provider XMax Inc
  • Michelangelo's Great Secret Hiding in Plain Sight
  • Larry R. Wasion's Jump Gate III RoadMaker Blends Cutting-Edge Sci-Fi with High-Stakes Space Exploration and Complex Technologies
  • Ed, Edd n Eddy, Resident Evil, Anime Voice Actors Augment FAN EXPO Philadelphia Lineup
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us